Dose and dosing frequency of long-acting injectable antipsychotics a systematic review of PET and SPECT data and clinical implications

Journal of Clinical Psychopharmacology

Volumn 34, Issue 6, 2014, Pages 728-735

  Uchida, Hiroyuki ^a,b   Suzuki, Takefumi ^a,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Inokashira Hospital   (Japan)

Author keywords

Antipsychotics; Depot; Dopamine; Long acting injection; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZUCLOPENTHIXOL; DELAYED RELEASE FORMULATION; DOPAMINE 2 RECEPTOR BLOCKING AGENT;

HUMAN; MAINTENANCE THERAPY; METHODOLOGY; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; RELAPSE; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADMINISTRATION AND DOSAGE; BRAIN; CROSS-SECTIONAL STUDY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; INTRAMUSCULAR DRUG ADMINISTRATION; PROSPECTIVE STUDY; SCINTISCANNING; TRENDS;

ANTIPSYCHOTIC AGENTS; BRAIN; CROSS-SECTIONAL STUDIES; DELAYED-ACTION PREPARATIONS; DOPAMINE D2 RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAMUSCULAR; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84925753086     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000065     Document Type: Review

References (56)

1. Uchida H, Suzuki T, Takeuchi H, et al. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull. 2011;37:788-799.
2. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(suppl 5):15-18.
3. Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl. 2009;52(suppl):1-4.
4. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophreniaVa critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127:83-92.
5. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006;67(suppl 5):9-14.
6. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1081-1090.
7. Farde L, Nyberg S, Oxenstierna G, et al. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995;15:19S-23S.
8. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520.
9. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:497-502.
10. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
11. Sakurai H, Bies RR, Stroup SE, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 2013;39:564-574.
12. Farde L, Hall H, Ehrin E, et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986;231:258-261.
13. Farde L, Halldin C, Stone-Elander S, et al. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology. 1987;92:278-284.
14. Baron JC, Martinot JL, Cambon H, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology. 1989;99:463-472.
15. Coppens HJ, Slooff CJ, Paans AM, et al. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry. 1991;29:629-634.
16. Harasko-van der Meer C, Brucke T, Wenger S, et al. Two cases of long-term dopamine D2 receptor blockade after depot neuroleptics. J Neural Transm. 1993;94:217-221.
17. Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152:173-178.
18. Nyberg S, Farde L, Bartfai A, et al. Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995;10:221-227.
19. Nyberg S, Farde L, Halldin C. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients. Psychiatry Res. 1996;67:163-171.
20. Nyberg S, Farde L, Halldin C. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Arch Gen Psychiatry. 1997;54:953-958.
21. Regenthal R, Kunstler U, Junhold U, et al. Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Int Clin Psychopharmacol. 1997;12:255-261.
22. Farde L, Suhara T, Nyberg S, et al. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology. 1997;133:396-404.
23. Tauscher J, Kufferle B, Asenbaum S, et al. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine. Psychopharmacology. 1997;133:102-105.
24. Kasper S, Tauscher J, Kufferle B, et al. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidolVa 123I-IBZM SPECT study. Psychopharmacology. 1998;136:367-373.
25. Nyberg S, Dencker SJ, Malm U, et al. D(2)-and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmacol. 1998;1:95-101.
26. Kuenstler U, Juhnhold U, Knapp WH, et al. Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs. Psychiatry Res. 1999;90:31-39.
27. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8:27-36.
28. Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163:396-401.
29. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008;33:298-304.
30. Uchida H, Mamo DC, Kapur S, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry. 2008;69:1281-1286.
31. Takeuchi H, Suzuki T, Uchida H, et al. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012;134:219-225.
32. Simpson GM, Mahmoud RA, Lasser RA, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2006;67:1194-1203.
33. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry. 1983;40:893-896.
34. Marder SR, Van Putten T, Mintz J, et al. Low-and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry. 1987;44:518-521.
35. Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Arch Gen Psychiatry. 1988;45:797-805.
36. Inderbitzin LB, Lewine RR, Scheller-Gilkey G, et al. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am J Psychiatry. 1994;151:1753-1759.
37. Huttunen MO, Tuhkanen H, Haavisto E, et al. Low-and standard-dose depot haloperidol combined with targeted oral neuroleptics. Psychiatr Serv. 1996;47:83-85.
38. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry. 1997;54:453-463.
39. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002;159:554-560.
40. Remington G, Kapur S. Antipsychotic dosing: how much but also how often? Schizophr Bull. 2010;36:900-903.
41. Remington G, Seeman P, Shammi C, et al. "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol. 2005;25:611-613.
42. Remington G, Seeman P, Feingold A, et al. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:1042-1048.
43. Mizuno Y, Bies RR, Remington G, et al. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:182-187.
44. Moriguchi S, Bies RR, Remington G, et al. Estimated dopamine D2 receptor occupancy and remission in schizophrenia: analysis of the CATIE data. J Clin Psychopharm. 2013;33(5):682-685.
45. Ikai S, Remington G, Suzuki T, et al. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. J Clin Psychiatry. 2012;73:1147-1152.
46. Post RM. Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci. 1980;26:1275-1282.
47. Carey RJ, DeVeaugh-Geiss J. Treatment schedule as a determinant of the development of tolerance to haloperidol. Psychopharmacology. 1984;82:164-167.
48. Turrone P, Remington G, Kapur S, et al. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005;57:406-411.
49. Bedard AM, Maheux J, Levesque D, et al. Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology. 2011;36:1248-1259.
50. Ng W, Uchida H, Ismail Z, et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 2009;31:360-366.
51. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:318-325.
52. Stone JM, Davis JM, Leucht S, et al. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugsVan original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull. 2009;35:789-797.
53. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063-2071.
54. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167:181-189.
55. Novakovic V, Adel T, Peselow E, et al. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). Clin Neuropharmacol. 2013;36:59-62.
56. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry. 1989;146:905-908.